SB-258719

SB-258719

Systematic (IUPAC) name
(1R)-3,N-dimethyl-N-[1-methyl-3-(4-methylpiperidin-1-yl)propyl]benzenesulfonamide
Identifiers
CAS Number	195199-95-2 N
PubChem	CID: 5312148
IUPHAR/BPS	281
ChemSpider	4471578 Y
ChEMBL	CHEMBL12264 Y
Chemical data
Formula	C18H32N2O2S
Molecular mass	340.523 g/mol
SMILES c1ccc(C)cc1S(=O)(=O)[NH2](C)C(C)CCN(CC2)CCC2C
InChI InChI=1S/C18H30N2O2S/c1-15-8-11-20(12-9-15)13-10-17(3)19(4)23(21,22)18-7-5-6-16(2)14-18/h5-7,14-15,17H,8-13H2,1-4H3/t17-/m1/s1 Y Key:AGVNHDNTFYHZNL-QGZVFWFLSA-N Y
NY (what is this?)  (verify)

SB-258719 is a drug developed by GlaxoSmithKline which acts as a selective 5-HT₇ receptor partial inverse agonist, and was the first such ligand identified for 5-HT₇. Its use in research has mainly been in demonstrating the potential use for 5-HT₇ agonists as potential novel analgesics, due to the ability of SB-258719 to block the analgesic effects of a variety of 5-HT₇ agonists across several different testing models.